ArticleAnimal models and experimental medicine2025
Establishment and molecular profiling of a PDX model of a metachronous brain tumor in a patient with constitutional mismatch repair deficiency with biallelic MSH6 variant.
Article in Animal models and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Outcomes of immunotherapy in medulloblastoma: a systematic review.The oncologist · 2026Pooled it
- Establishment and molecular profiling of a PDX model of a metachronous brain tumor in a patient with constitutional mismatch repair deficiency with biallelic MSH6 variant.Animal models and experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundConstitutional mismatch repair deficiency (CMMRD) is a rare disorder resulting from biallelic germline pathogenic variants in mismatch repair genes. This study described the molecular profile of two metachronous brain tumors and a patient-derived xenograft (PDX) from a Brazilian child with CMMRD.
methodsAfter PDX development, methylation array, whole exome sequencing, and NanoString techniques were applied to describe the genetic landscape of CMMRD.
resultsA 6½-year-old girl was diagnosed with Sonic Hedgehog (SHH)-activated medulloblastoma and somatic TP53-mutant. After surgery and radiochemotherapy, she remained free of disease progression. At 10 years and 3 months, she developed a diffuse pediatric-type high-grade glioma (dpHGG). The child had a family history of cancer, and subsequent investigation revealed a biallelic germline variant on MSH6 (c.3556+1G>A) with the absence of protein expression in both normal and tumor tissue. A PDX model of the dpHGG was developed. The methylation profile confirmed the diagnosis of both brain tumors and PDX, refining the classification of dpHGG, Rtk1 subtype, subclass A, with an actionable alteration on Platelet-derived growth factor receptor A (PDGFRA). Exome analysis showed high tumor mutational burden, with 3019, 540, and 1049 pathogenic variants in the medulloblastoma, dpHGG, and PDX, respectively. Only the medulloblastoma exhibited microsatellite instability. The CD24, CD47, and CD276 immune checkpoints had elevated messenger RNA levels, yet no programmed death ligand 1 expression was observed in CMMRD-derived tumors.
conclusionWe report an extensive molecular profile of a CMMRD patient, and the developed PDX model can be applied to explore new therapeutic approaches for CMMRD-associated brain tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.